Brain and Nerves |
|
|
Clinical Trial: A Phase I Study of Tomotherapy in Patients with Benign Brain Tumour
This study is currently recruiting patients.
Verified by Alberta Cancer Board July 2005
Purpose
Although malignant brain tumors are the most common type of primary brain tumor, there are a number of other benign brain tumors that exist. Many difficulties exist with treating these tumors have led to controversies in the best treatment. A common issue among these brain tumors is the risk of long term side effects from treatment. What limits the use of curative raditation therapy is the ability to deliver a maximal dose to the tumor while minimizing the amount of radiation to the normal structures in the brain. A new method of delivering radiation called tomotherapy has been acquired at the CCI and will be used in this study. It has the ability to deliver a high dose of radiation to the tumor while minimizing the amount of radiation to normal brain structures. This study will use this method of radiation therapy to deliver radiation and see if the long term side effects from radiation therapy can be reduced.
| Condition | Intervention | Phase |
|---|---|---|
| -brain neoplasms -brain | Procedure: Tomotherapy | Phase I |
MedlinePlus related topics: Brain Cancer; Brain Diseases
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety Study
Further Study Details:
Primary Outcomes: -safety and adverse effects
Secondary Outcomes: -efficacy and survival
Expected Total Enrollment: 50
Secondary Outcomes: -efficacy and survival
Expected Total Enrollment: 50
Study start: May 2005
Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- histopathologically confirmed newly diagnosed base of skull benign tumour
- KPS equal to or greater than 70
Exclusion Criteria:
- brain metastases or recurrent tumour
- prior to RT head or neck
- no prior chemo or radiosensitizer
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00128986
Wilson Roa, MD 780-432-8783 wilsonro@cancerboard.ab.ca
Canada, Alberta
Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada; Recruiting
Paula Langenhoff 780-432-8909 paulalan@cancerboard.ab.ca
Wilson Roa, MD, Principal Investigator
Wilson Roa, MD, Principal Investigator
Study chairs or principal investigators
Wilson Roa, MD, Principal Investigator, Alberta Cancer Board
More Information
Study ID Numbers: CNS-09-0029
Last Updated: August 10, 2005
Record first received: August 9, 2005
ClinicalTrials.gov Identifier: NCT00128986
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 10, 2005
Record first received: August 9, 2005
ClinicalTrials.gov Identifier: NCT00128986
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-08-23

Not Signed In -

